Related Experiment Videos

Genetic polymorphisms of the RAS-cytokine pathway and chronic kidney disease

Craig Wong1, Peter Kanetsky, Dominic Raj

  • 1Department of Pediatrics, Division of Nephrology, Albuquerque, NM, USA. cwong@salud.unm.edu

Pediatric Nephrology (Berlin, Germany)
|May 16, 2008
PubMed

Insights

Genetic factors influence pediatric chronic kidney disease (CKD) and cardiovascular disease. Genome-wide association studies may reveal shared genetic risks and inform targeted interventions for children with CKD.

Area of Science:

  • Nephrology
  • Genetics
  • Cardiology

Background:

  • Pediatric chronic kidney disease (CKD) is irreversible, leading to renal failure and cardiovascular (CV) disease.
  • Congenital or inherited disorders affect nearly 60% of children with CKD.
  • Adult CKD studies suggest shared genetic risk factors between CKD and atherosclerotic CV disease.

Purpose of the Study:

  • Investigate common genetic risk factors for CKD and atherosclerotic CV disease in children.
  • Explore the role of the renin-angiotensin system (RAS) and inflammatory pathways in CKD progression and CV abnormalities.
  • Utilize genome-wide association studies (GWAS) to identify genetic modulators of CKD and associated CV risks.

Main Methods:

  • Review of preliminary evidence from adult CKD studies on shared genetic risk factors.
  • Focus on the renin-angiotensin system (RAS) and inflammatory cascade pathways.
  • Application of genome-wide association studies (GWAS) for identifying single nucleotide polymorphisms (SNPs) in polygenic diseases like CKD.

Main Results:

  • Preliminary evidence suggests common genetic risk factors for CKD and atherosclerotic CV disease, particularly within the RAS-cytokine pathway.
  • Gene polymorphisms in the RAS-cytokine pathway may modulate CKD progression and CV abnormalities through altered inflammatory cytokine expression.
  • GWAS offers a paradigm for studying polygenic diseases like CKD, despite potential weaknesses requiring careful interpretation.

Conclusions:

  • Shared genetic factors likely contribute to both CKD and cardiovascular disease in children.
  • The RAS and inflammatory pathways are critical targets for understanding CKD progression and associated CV risks.
  • Whole-genome association studies hold promise for developing targeted interventions for pediatric CKD and its cardiovascular complications.

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...